Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020 – Paradigm Shift to Non-Estrogenic Therapies – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global
Post Menopausal Vaginal Atrophy Drugs Market 2016-2020″ report
to their offering.

The report forecasts the global PVA drugs market to grow at a CAGR of
7.13% during the period 2016-2020.

The report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the market landscape and
its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.

Non-estrogenic therapies in PVA treatment are a paradigm shift from
systemic estrogen therapies such as creams, patches, and gels. In
addition, the launch of late-stage pipeline products is expected to
shift the attention from vaginal creams and OTC classes toward vaginal
tablets and oral therapies.

According to the report, the Affordable Care Act has increased the
number of insured women and has been a driving factor in the
treatment-seeking behavior of people with this condition. The law puts
in place comprehensive health insurance reforms that will roll out over
four years and beyond. This provides Americans with better health
security by putting in place comprehensive health insurance reforms that
lower healthcare costs and expand the coverage.

Further, the report states that the market is currently served by
generic products due to the patent expiries of branded products such as
Premarin, which lost its patent in 2012.

Key vendors:

• Pfizer Inc.
• Allergan Inc.
• Shionogi & Co. Ltd.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Overview: Vaginal atrophy

PART 06: Branded drug profiles

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

PART 16: Appendix

For more information visit http://www.researchandmarkets.com/research/rl77g4/global_post

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women’s
Health